Marcadores bioquímicos propuestos para el estudio de la sarcopenia / Proposed biochemical markers for the study of sarcopenia

La sarcopenia asociada a la edad es una condición clínica caracterizada por una disminución en la fuerza, calidad y cantidad de masa muscular así como también en la función muscular. Un biomarcador se define como una característica que es medible objetivamente y evaluable como indicador de un proceso biológico normal, patológico o respuesta terapéutica a una intervención farmacológica. Los marcadores bioquímicos propuestos para el estudio de la sarcopenia pueden ser categorizados en dos grupos. El primero de ellos evalúa el estatus musculoesquelético; este panel de marcadores está formado por miostatina/folistatina, procolágeno aminoterminal tipo III e índice de sarcopenia. El segundo grupo de marcadores bioquímicos evalúa factores causales, para lo cual se sugiere medir el factor de crecimiento insulino-símil tipo 1 (IGF-1), dehidroepiandrosterona (DHEAS), cortisol, facto-res inflamatorios [proteína C reactiva (PCR), interleuquina 6 (IL-6) y factor de necrosis tu-moral (TNF-a)]. Las recomendaciones realiza-das están basadas en la evidencia científica disponible en la actualidad y la disponibilidad de la metodología apropiada para cada uno de los biomarcadores. (AU)

Sarcopenia is a progressive and generalized skeletal muscle disorder defined by decrease in the strength, quality and quantity of muscle mass as well as in muscle function. A biomarker is defined as a feature objectively measured and evaluated as an indicator of a normal biologic process, a pathogenic process or a pharmacologic response to therapeutic intervention. The biochemical markers proposed for the study of sarcopenia may be classified in two groups. The first group evaluates the musculoskeletal status, made up by myostatin/follistatin, N-terminal Type III Procollagen and the sarcopenia index. The second evaluates causal factors, where the measurement of the following is suggested: hormones insulin-like growth factor-1 (IGF-I), dehydroepiandrosterone sulphate (DHEAS), cortisol, inflammatory factors [C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-a (TNF-a)]. The recommendations made are based on scientific evidence currently available and the appropriate methodology availability for each biomarker. (AU)

Comparison of diagnosis frequency between versions of the European Consensus on Sarcopenia: a cross-sectional study / Comparação da frequência de diagnóstico entre as versões do Consenso Europeu sobre Sarcopenia: um estudo transversal

OBJECTIVE: To compare sarcopenia diagnosis according to 2 versions of the European Consensus on Sarcopenia (EWGSOP and EWGSOP2) in a sample of older adults. METHOD: This cross-sectional study included 82 community-dwelling older people from Porto Alegre, Brazil. The patients were assessed by trained professionals and were classified according to the criteria of the 2 versions of the consensus to show the differences between the classification models. RESULTS: The participants performed the Timed Up and Go test in < 7.21 seconds. On average, their performance on the 6-meter walk test was above the predicted value. Only 3 patients had a gait speed < 0.8 m/s. Handgrip strength was, on average, the predicted percentage. In the Short Physical Performance Battery, the scores of a few were intermediate but most were high. According to EWGSOP criteria, 92.18% were non-sarcopenic and 7.81% had severe sarcopenia, while according to EWGSOP2 criteria, 98.43% were non-sarcopenic, 1.56% were sarcopenic, and none had severe sarcopenia. The rate of sarcopenia diagnosis, which was 8.53% according to EWGSOP criteria, reduced to 3.65% according to EWGSOP2 criteria and the new cut-off points (p = 0.034). CONCLUSION: Although our sample was small, the reduction was significant, indicating that the change in criteria, even with lower cut-off points, reduced the probability of early diagnosis

OBJETIVO: Comparar a aplicação dos critérios e orientações das duas versões do Consenso Europeu sobre Sarcopenia (EWGSOP e EWGSOP2) para o diagnóstico e classificação, numa amostra de idosos residentes na comunidade. METODOLOGIA: Estudo transversal, com 82 idosos residentes na comunidade da cidade de Porto Alegre. Os pacientes foram avaliados por profissionais treinados e classificados segundo os critérios dos dois consensos para mostrar as diferenças entre os dois modelos de classificação.RESULTADOS: Em testes físicos como o timed up and go, a amostra realizou o teste em menos de 7,21 segundos. Em média, os idosos conseguiram caminhar no teste de caminhada de 6 metros mais do que a percentagem prevista para esse público. Apenas três pacientes apresentaram velocidade de caminhada inferior a 0,8 m/s. Na avaliação de força, os idosos conseguiram atingir, em média, o percentual previsto. No Short Physical Performance Battery, poucos tiveram desempenho intermediário. A maioria teve desempenho alto. Quando avaliados pelo EWGSOP, 92,18% eram não sarcopênicos, enquanto 7,81% eram sarcopênicos severos; e, quando avaliados pelo EWGSOP2, 98,43% eram não sarcopênicos, 1,56% sarcopênico e nenhum sarcopênico severo. A aplicação dos critérios EWGSOP2 e novos pontos de corte reduziram a capacidade de diagnóstico de sarcopenia na amostra de 8,53 para 3,65% (p = 0,034).CONCLUSÃO: Embora a amostra seja pequena, a redução é significativa e expressa que a mudança de critério, mesmo utilizando pontos de corte mais baixos para a amostra em análise, trouxe impacto no sentido de não diagnosticar precocemente

Risk of sarcopenia in older adults with type 2 diabetes mellitus: evaluation of the SARC-F and SARC-CalF as screening tools / Risco de sarcopenia em idosos com diabetes mellitus tipo 2: avaliação do SARC-F e SARC-CalF como ferramentas para rastreamento

Objective: To evaluate the diagnostic power of SARC-F and SARC-CalF as screening tools for sarcopenia risk in older adults with type 2 diabetes mellitus. Methods: This cross-sectional study of 128 patients was conducted at the endocrinology outpatient clinic of a hospital in Recife, Brazil between July 2022 and February 2023. Sarcopenia was diagnosed according to original and updated European Consensus criteria for older adults. Muscle mass was assessed with electrical bioimpedance, muscle strength was assessed with a handgrip test, and physical performance was assessed with gait speed. Sarcopenia risk was assessed using the SARC-F and SARC-CalF instruments. The sensitivity, specificity, positive and negative predictive values, receiver operating characteristic curve, and area under the curve were analyzed to determine the best diagnostic performance. Results: According to the original and updated versions of the European Consensus criteria, the prevalence of sarcopenia was 25.00% and 10.90%, respectively. Sarcopenia risk was 17.20% according to the SARC-F and 23.40% according to the SARC-CalF. The sensitivity and specificity of the SARC-F ranged from 12.55% to 36.11% and 71.87% to 92.39%, respectively, while those of the SARC-CalF ranged from 47.22% to 85.71% and 82.46% to 88.89%, respectively. The area under the curve for the SARC-F and SARC-CalF varied between 0.51 and 0.71 and 0.67 and 0.86, respectively. Conclusions: The SARC-CalF had better diagnostic performance for all analyzed diagnostic criteria. Adding calf circumference to the SARC-F was an effective screening method for sarcopenia risk in the study population

Objetivo: Avaliar o poder diagnóstico do SARC-F e SARC-CalF como ferramentas de rastreamento para o risco de sarcopenia em idosos com diabetes mellitus tipo 2. Metodologia: Estudo transversal com 128 pacientes desenvolvido no ambulatório de endocrinologia de um hospital do Recife entre julho de 2022 e fevereiro de 2023. A sarcopenia foi diagnosticada de acordo com os critérios do Consenso Europeu para sarcopenia em pessoas idosas e sua versão atualizada. Foi realizada bioimpedância elétrica para avaliar a massa muscular, teste de preensão palmar para a força muscular e teste de velocidade de marcha para a performance física. O risco para sarcopenia foi avaliado por meio do SARC-F e SARC-CalF. Realizou-se análise de sensibilidade, especificidade, valores preditivos positivos e negativos, curva Característica de Operação do Receptor (ROC) e área sob a curva (AUC) para determinar a melhor performance diagnóstica. Resultados: A prevalência de sarcopenia foi de 25,00% de acordo com a primeira versão do Consenso Europeu e 10,90% considerando a versão atualizada. O risco para sarcopenia foi de 17,20% (SARC-F) e 23,40% (SARC-CalF). A sensibilidade do SARC-F variou entre 12,55 e 36,11%, e a espec ificidade entre 71,87 e 92,39%, enquanto o SARC-CalF apresentou sensibilidade entre 47,22 e 85,71% e especificidade entre 82,46 e 88,89%. A AUC do SARC-F variou entre 0,51 e 0,71, enquanto o SARC-CalF ficou entre 0,67 e 0,86. Conclusões: O SARC-CalF apresentou melhor performance diagnóstica quando comparado a todos os critérios diagnósticos analisados. A adição da circunferência da panturrilha é um método eficaz para o rastreamento do risco de sarcopenia na população do estudo

Machine and deep learning-based clinical characteristics and laboratory markers for the prediction of sarcopenia / 中华医学杂志(英文版)

BACKGROUND@#Sarcopenia is an age-related progressive skeletal muscle disorder involving the loss of muscle mass or strength and physiological function. Efficient and precise AI algorithms may play a significant role in the diagnosis of sarcopenia. In this study, we aimed to develop a machine learning model for sarcopenia diagnosis using clinical characteristics and laboratory indicators of aging cohorts.@*METHODS@#We developed models of sarcopenia using the baseline data from the West China Health and Aging Trend (WCHAT) study. For external validation, we used the Xiamen Aging Trend (XMAT) cohort. We compared the support vector machine (SVM), random forest (RF), eXtreme Gradient Boosting (XGB), and Wide and Deep (W&D) models. The area under the receiver operating curve (AUC) and accuracy (ACC) were used to evaluate the diagnostic efficiency of the models.@*RESULTS@#The WCHAT cohort, which included a total of 4057 participants for the training and testing datasets, and the XMAT cohort, which consisted of 553 participants for the external validation dataset, were enrolled in this study. Among the four models, W&D had the best performance (AUC = 0.916 ± 0.006, ACC = 0.882 ± 0.006), followed by SVM (AUC =0.907 ± 0.004, ACC = 0.877 ± 0.006), XGB (AUC = 0.877 ± 0.005, ACC = 0.868 ± 0.005), and RF (AUC = 0.843 ± 0.031, ACC = 0.836 ± 0.024) in the training dataset. Meanwhile, in the testing dataset, the diagnostic efficiency of the models from large to small was W&D (AUC = 0.881, ACC = 0.862), XGB (AUC = 0.858, ACC = 0.861), RF (AUC = 0.843, ACC = 0.836), and SVM (AUC = 0.829, ACC = 0.857). In the external validation dataset, the performance of W&D (AUC = 0.970, ACC = 0.911) was the best among the four models, followed by RF (AUC = 0.830, ACC = 0.769), SVM (AUC = 0.766, ACC = 0.738), and XGB (AUC = 0.722, ACC = 0.749).@*CONCLUSIONS@#The W&D model not only had excellent diagnostic performance for sarcopenia but also showed good economic efficiency and timeliness. It could be widely used in primary health care institutions or developing areas with an aging population.@*TRIAL REGISTRATION@#Chictr.org, ChiCTR 1800018895.

Inadequate distribution of dietary protein and muscle mass in older adults

Objective: To assess protein intake, protein distribution across meals, and a possible association between protein distribution and muscle mass in older adults. Methods: This cross-sectional study included 47 older adults attending a community center in Campo Grande, MS, Brazil. A sociodemographic questionnaire was used to characterize the population. Dietary intake data were collected using two 24-hour dietary recalls on nonconsecutive days. Anthropometric measures, such as weight, height, and body circumferences, and measures of handgrip strength were collected. Skeletal muscle mass was calculated from the anthropometric measures. Descriptive statistics were used to derive means and standard deviations. Analysis of variance and Tukey tests were performed, with a significance level of 5% (p < 0.05). Results:The older adults, mostly Caucasian, female, physically active, at risk of malnutrition, and with a low level of education, had an energy intake of 1,305.28 kcal/day. Protein intake was 65.19 g/day, with a mean of 0.93 g/kg/day. Lunch was the meal with the highest protein intake (33.85 ± 2.47 g). The lowest protein intake was observed at breakfast (8.56 ± 0.82 g). All meals were below the recommendation of 40 g of protein/meal. Protein intake at breakfast was associated with calf circumference (p = 0.04). Conclusions: The older adults consumed a low amount of total and per-meal protein. Breakfast showed the lowest protein intake, and this was associated with calf circumference in the study sample.

Objetivo: Avaliar o consumo proteico, sua distribuição nas principais refeições e sua possível associação com a massa muscular de idosos. Metodologia: Estudo transversal realizado com 47 idosos frequentadores de um centro de convivência em Campo Grande (MS). Aplicou-se um questionário sociodemográfico e dois recordatórios de 24 horas, em dias alternados, para a avaliação do consumo alimentar, e realizou-se avaliação antropométrica por meio da aferição de medidas como peso, estatura, circunferências corporais e a força de pressão palmar. Com as medidas antropométricas, foi calculada a quantidade de massa muscular esquelética. Realizou-se estatística descritiva e, para as análises de associação, aplicaram-se os testes de variância (ANOVA) e de Tukey, com significância estatística quando p < 0,05. Resultados: Os idosos, majoritariamente caucasianos, do sexo feminino, fisicamente ativos, em risco de desnutrição e com escolaridade reduzida apresentaram consumo energético de 1.305,28 kcal/dia e consumo proteico 65,19 g/dia, sendo 0,93 g de proteína/kg/dia. O almoço foi a refeição com maior aporte proteico (33,85 ± 2,47 g). O menor consumo proteico foi observado no café da manhã (8,56 ± 0,82 g). Todas as refeições ficaram abaixo da recomendação de 40 g de proteína/refeição. O consumo proteico no café da manhã associou-se à circunferência da panturrilha (p = 0.04). Conclusões: Os idosos consumiram baixa quantidade de proteínas totais e nas principais refeições. O café da manhã foi a refeição com menor aporte proteico e este associou-se à circunferência da panturrilha em idosos da amostra.

Phase angle as a screening method for sarcopenia in community-dwelling older adults / Ângulo de fase como método de triagem para sarcopenia em idosas ativas de comunidade

ABSTRACT Objective We investigated the utility of the phase angle as a screening tool for sarcopenia. Methods We performed a cross-sectional study that included 169 active community-dwelling elderly women. The phase angle was determined using tetrapolar bioelectrical impedance, and sarcopenia was diagnosed based on skeletal muscle mass, muscle strength, and physical performance using bioelectrical impedance analysis, a handheld dynamometer, and the gait speed test, respectively. Receiver operating characteristic curve analysis was performed to investigate the role of the phase angle as a predictor of sarcopenia. Results The prevalence of sarcopenia was 12.4%. The median phase angle was 5.30°; elderly women with sarcopenia had lower phase angles than those without sarcopenia (p=0.006). The phase angle cutoff for the detection of sarcopenia was ≤5.15°, with an area under the curve of 0.685, sensitivity 81.0%, specificity 60.8%, and accuracy 63.31%. Elderly women with a low phase angle show a high risk of presenting with reduced muscle mass. Conclusions The phase angle was shown to be a useful screening tool in elderly women with sarcopenia.

RESUMO Objetivo Avaliar o ângulo de fase como método de triagem para sarcopenia. Métodos Estudo transversal realizado com 169 idosas ativas de comunidade. O ângulo de fase foi obtido por bioimpedância elétrica tetrapolar e a sarcopenia foi diagnosticada a partir da massa muscular esquelética, força muscular e performance física utilizando bioimpedância elétrica, dinamometria manual e o teste de velocidade de marcha, respectivamente. A curva Receiver Operating Characteristic foi construída para avaliar o ângulo de fase como preditor de sarcopenia. Resultados A prevalência de sarcopenia foi de 12,4%. A mediana do ângulo de fase foi de 5,30°; idosas com sarcopenia apresentaram valores menores do ângulo de fase em relação às não sarcopênicas (p=0,024). O ponto de corte do ângulo de fase para identificar sarcopenia foi ≤5,15°, com área sob a curva de 0,685, sensibilidade de 81,0%, especificidade de 60,8% e acurácia de 63,31%. Observou-se que idosas com ângulo de fase reduzido apresentaram maior chance de terem massa muscular reduzida e sarcopenia. Conclusão O ângulo de fase se mostrou útil para triagem de idosas com sarcopenia.

Cross-validation of 20 anthropometric prediction equations for appendicular muscle mass in older Brazilian women: a cross-sectional study / Validação cruzada de 20 equações antropométricas de massa muscular apendicular para idosas brasileiras: um estudo transversal

Objective: To test the cross-validation of anthropometric prediction equations for appendicular muscle mass (AMM) in older Brazilian women. Methods: Sixty-seven older women (69.84 ± 5.95 years old) underwent anthropometric measurements. AMM (kg) reference values obtained by dual-energy X-ray absorptiometry (AMMDXA) were compared to 20 anthropometric equations for estimating AMM in older adults. A paired t-test (p > 0.05), standard error of estimate (SEE < 3.50 kg), and r2 > 0.70 confirmed the validity of the equations. The agreement between predictions and the reference was also verified (Bland-Altman analysis of agreement between methods). Results: Four American equations and one Mexican equation were not statistically different from AMMDXA (p > 0.05) but did not present suitable r2 values for validation. The American equation from the National Health and Nutrition Examination Survey (NHANES), AMM (kg) = (-0.04 × age [years]) + (0.46 × calf circumference [cm]) + (0.32 × arm circumference [cm]) + (0.11 × thigh circumference [cm]) ­ (0.27 × body mass index [BMI, kg/m2 ]) + (0.07 × waist circumference [cm]) ­ 13 119 showed the best performance (r2 = 0.64; SEE = 3.24 kg), with minimal mean difference (0.26 kg), no heteroscedasticity for extreme values, and with high agreement with the Brazilian sample (-3.90 to 3.40 kg). Conclusion: When specific equations for a given population are not available, the use of generic equations of greater sample representativeness with scientifically and reliably analyzed data is allowed.

Objetivo: Testar a validação cruzada das equações antropométricas preditivas da massa muscular apendicular (MMA) em idosas brasileiras. Metodologia: Sessenta e sete idosas (69,84 ± 5,95 anos) foram submetidas a medidas antropométricas. Os valores de referência da MMA (kg) fornecida pela absorciometria de raios X de dupla energia (MMADXA) foi comparada com 20 equações antropométricas preditivas para estimar a MMA para idosos. Teste t pareado (p > 0,05), erro padrão de estimativa (EPE) < 3,50 kg e r2 > 0,70 confirmaram a validade das equações. A concordância entre as previsões e a referência também foi verificada (análise de concordância entre métodos de Bland-Altman). Resultados: Quatro equações americanas e uma equação mexicana não foram estatisticamente diferentes da MMADXA (p > 0,05), mas nenhuma delas apresentou r2 adequado para validação. A equação americana dos dados do National Health and Nutrition Examination Survey (NHANES), MMA (kg) = (-0,04 × idade [anos]) + (0,46 × circunferência da panturrilha [cm]) + (0,32 × circunferência do braço [cm]) + (0,11 × circunferência da coxa [cm]) ­ (0,27 × índice de massa corporal-IMC [kg/m2 ]) + (0,07 × circunferência da cintura [cm]) ­ 13,12 apresentou o melhor desempenho (r2 = 0,64; EPE = 3,24 kg): com diferença média mínima (0,26 kg), sem heterocedasticidade para valores extremos e alta concordância com a amostra brasileira (-3,90 a 3,40 kg). Conclusão: Quando não existem equações específicas para uma determinada população, é permitida a utilização de equações genéricas de maior representatividade amostral, cujos dados tenham sido analisados de forma científica e confiável

¿Qué se debería evaluar frente al paciente adulto mayor con cáncer? / What should we evaluate in an older adult with cancer?

En la medida en que el crecimiento poblacional continúe en aumento, la cantidad de adultos mayores que sufran patología oncológica será cada vez mayor. Esta población, por su heterogeneidad y su comorbilidad diferente de la del adulto joven, requiere un manejo más específico e individualizado. La realización de una valoración geriátrica integral y el trabajo multidisciplinario, colaborarán en la toma de decisiones con el fin de priorizar la calidad de vida de cada paciente en particular y optimizar el manejo de los pacientes vulnerables. (AU)

As the population grows, there will be more cancer diagnoses in the elderly population. This group, due to its heterogeneity and comorbidities different from those of young adults, requires a specific and individualized assessment. The geriatric assessment and multidisciplinary work, together, would help in decision-making in order to prioritize the quality of life of each patient and optimize management of the vulnerable patients.Key words: elderly, geriatric assessment, frailty, cancer, sarcopenia, abilities of daily living. (AU)

A low phase angle determined by bioelectrical impedance analysis is associated with oropharyngeal dysphagia among institutionalized older adults

SUMMARY OBJECTIVE The aim was to evaluate the prevalence of oropharyngeal dysphagia (OD) and its association with body composition by bioelectrical impedance analysis (BIA) and functionality among institutionalized older adults. METHODS A cross-sectional study was conducted. The swallowing function and diagnosis of OD were evaluated with a volume-viscosity swallow test. Activities of daily living were evaluated by the Barthel Index. Body composition was evaluated by BIA, and phase angle (PhA) was determined. RESULTS Eighty institutionalized older adults were evaluated. The mean age of the study population was 82±9.5 years, and 65% were females. The OD prevalence was 30%, dependence was 30%, and sarcopenia was 16%. In the multivariate analysis, a low PhA (<3.5°) was independently associated with the presence of OD adjusted by sex and age (OR: 2.60, 95%CI 2.41-2.90, p=0.01). CONCLUSIONS A higher prevalence of OD was found. Significant and independent associations were found between low PhA, dependence, and sarcopenia with the presence of OD among institutionalized older persons.

Pharmacological Treatment of Sarcopenia Tratamento medicamentoso da sarcopenia / Tratamento medicamentoso da sarcopenia Pharmacological Treatment of Sarcopenia

Abstract Sarcopenia has been acquiring a growing importance in the scientific literature and in doctors' offices. As the population ages, it becomes increasingly essential to know, prevent, and treat this clinical condition. The purpose of the present review is to bring up the current evidence on the diagnosis of this pathology, in a practical way, as well as the main current treatment options.

Resumo A sarcopenia vem ganhando cada vez mais importância na literatura científica e nos consultórios médicos. Com o envelhecimento da população, essa condição clínica se torna cada vez mais imprescindível de se conhecer, se prevenir e de se tratar. O objetivo desta revisão é trazer as evidências atuais sobre o diagnóstico dessa patologia, de forma prática, bem como as principais opções atuais de tratamento.

Índice de sarcopenia en pacientes hospitalizados por agudización de la enfermedad pulmonar obstructiva crónica / Sarcopenia index in hospitalized patients with chronic obstructive pulmonary disease exacerbation

Resumen La presencia de sarcopenia (pérdida de masa y función muscular) implica peor pronóstico. Sin embargo, su diagnóstico es complejo y no se realiza en la atención clínica habitual. Se ha propuesto un biomarcador como estimador subrogado de la masa muscular esquelética, el denominado índice de sarcopenia ([creatinina sérica/cistatina C] x100) que se asocia a características pronósticas en diversas enfermedades incluyendo pacientes con enfermedad pulmonar obstructiva crónica (EPOC) estable. El objetivo de nuestro estudio ha sido evaluar de forma prospectiva la potencial información clínica y pronóstica de este biomarcador en agudización de la EPOC. Se trata de un estudio prospectivo, durante un año, de los pacientes consecutivos que ingresan por agudización de su EPOC. Se incluyeron 89 pacientes, 70 varones (79%) y 19 mujeres (21%). Aquellos con valores disminuidos del índice de sarcopenia tenían más disnea y requerían una internación más prolongada. En el análisis de correlación se obtuvo valores con significación estadística del índice con FEV1 (r = 0.23), PaCO (r = -0.30) y bicarbonato (r = -0.31), y con la disnea (r = -0.25) y la duración del ingreso (r =0.30). En los ingresados por agudización de la EPOC el índice de sarcopenia se relacionó con características pronósticas, de modo que los valores inferiores se asociaron a mayor duración de la internación, más disnea y mayor afectación funcional. Al tratarse de un índice asociado a la masa muscular, su determinación podría identificar a pacientes a incluir en un plan terapéutico diferenciado.

Abstract Sarcopenia (loss of muscle mass and function) implies a worse prognosis. However, its diagnosis is complex and is not made in routine clinical care. A biomarker has been proposed as a surrogate estimator of skeletal muscle mass, the so-called sarcopenia index ([serum creatinine/cystatine C] x100) which is associated with prognostic features in various diseases including patients with stable chronic obstructive pulmonary disease (COPD). The aim of our study was to prospectively evaluate the potential clinical and prognostic information of this biomarker in COPD exacerbation. This is a one-year prospective study of consecutive patients admitted for COPD exacerbation. A total of 89 patients, 70 men (79%) and 19 women (21%) were included. Those with lower values of the sarcopenia index had a higher level of dyspnoea and a longer hospitalization. In the correlation analysis, the index had statistically significant values with FEV1 (r = 0.23), PaCO (r = -0.30), bicarbonate (r = -0.31), dyspnoea (r = -0.25) and length of admission (r = -0.30). In patients admitted for COPD exacerbation, the sarcopenia index was related to prognostic characteristics, so that lower values were associated with longer duration of hospital admission, more dyspnoea and greater functional impairment. As this is an index associated with muscle mass, its determination may identify patients who could be the subject of a differentiated therapeutic plan.

Predictors of sarcopenia in young hospitalized patients living with HIV

ABSTRACT The prevalence of sarcopenia in hospitalized people living with HIV is underdiagnosed, as assessment instruments are not always available. This study aimed to identify factors related to sarcopenia, correlating their anthropometric and clinical markers in hospitalized people living with HIV. This was an observational cross-sectional clinical study, carried out from September 2018 through October 2019. Handgrip strength, muscle mass index, calf circumference and gait speed test were evaluated in recruited patients within three days of hospital admission. The sample consisted in 44 patients, mostly men (66%), black (68%), young adults (41.65 ± 12.18 years) and immunodeficient (CD4 cell count 165 cells/mm3 [34.25-295.5]). Sarcopenia was present in 25% of the sample. Calf circumference showed a significant correlation with CD4 cell count and viral load (p < 0.05) while handgrip strength and gait speed test did not. Calf circumference > 31 cm and gait speed test > 0.8 m/s reduced the chance of sarcopenia by 60% (OR = 0.396 [−1.67 to −0.18]; p < 0.05) and 98% (OR = 0.02 [−8.16 to 0.13]; p < 0.05) respectively. Calf circumference > 31 cm and gait speed test > 0.8 m/s are associated with a reduced chance of sarcopenia in hospitalized HIV patients.

Sarcopenia, definición y diagnóstico: ¿Necesitamos valores de referencia para adultos mayores de Latinoamérica? / Sarcopenia, definition and diagnosis: do we need reference values in older adults from latin america?

La sarcopenia es uno de los principales síndromes geriátricos que está asociada con limitación en las actividades de la vida diaria, discapacidad y mortalidad en la población adulta mayor. Sin embargo, su definición, criterios diagnósticos y puntos de corte son diversos en la literatura, lo que dificulta el diagnóstico de la sarcopenia. El objetivo de esta revisión narrativa fue detectar en la literatura todos los consensos internacionales relacionados con sarcopenia, comparar su definición, criterios diagnósticos y puntos de corte, con el propósito de identificar una definición y criterios que puedan ser utilizados en Latinoamérica. Fueron identificados 7 consensos internacionales que han definido la sarcopenia como un síndrome/enfermedad caracterizado por la pérdida de la masa y función muscular asociada al proceso de envejecimiento. A pesar de tener una definición similar, no hay una total concordancia entre los criterios y evaluaciones. La sarcopenia puede ser detectada utilizando evaluaciones funcionales de fuerza muscular, velocidad de la marcha y equilibrio, que son frecuentemente utilizados por profesionales del área de la rehabilitación. Adicionalmente, el riesgo de sarcopenia puede ser identificado utilizando los cuestionarios SARC-F y SARC-CalF. Debido a su impacto funcional, la sarcopenia debería ser diagnosticada precozmente en adultos mayores por terapeutas ocupacionales, kinesiólogos y fisioterapeutas, para prevenir y tratar futuras complicaciones clínicas y funcionales en esta población. Es necesario la creación de valores de referencia para favorecer el diagnóstico de la sarcopenia en población latinoamericana.

Sarcopenia is one of the main geriatric syndromes that has been associated with limitation in activities of daily living, disability, and mortality in the elderly population. However, the definition, diagnostic criteria and cut-off points are diverse in the literature, which makes the diagnosis of sarcopenia difficult. The aim of this narrative review was to detect in the literature all the international consensus related to sarcopenia, to compare their definition, diagnostic criteria and cut-off points, in order to identify a definition and criteria that can be used in Latin America. Seven international consensuses were identified that have defined sarcopenia as a syndrome / disease characterized by loss of muscle mass and function associated with the aging process. Despite having a similar definition, there is not a total concordance between the criteria and evaluations. Sarcopenia can be detected using functional assessments of muscle strength, gait speed, and balance, which are frequently used by professionals in the area of rehabilitation. Additionally, the risk of sarcopenia can be assessed using SARC-F and SARC-CaF. Due to its functional impact, sarcopenia should be diagnosed early in older adults by occupational therapists, physical therapists and physiotherapists, to prevent and treat future clinical and functional complications in this population. The creation of reference values is necessary to favor the diagnosis of sarcopenia in the Latin American population.

Sarcopenia y factores relacionados en mujeres mayores de 40 años / Sarcopenia and related factors in women over 40 years

Introducción: La disminución de la masa muscular o sarcopenia y de la masa ósea (osteopenia u osteoporosis) que ocurren con el envejecimiento, se asocian con aumento de la fragilidad y las fracturas, que afectan calidad de vida e incrementan mortalidad. Los reportes sobre masa muscular son escasos en nuestro medio. Objetivos: Identificar los valores de referencia normal de la masa muscular en mujeres del área de referencia, la frecuencia de Sarcopenia con el empleo de los tres parámetros recomendados por el Consenso Europeo, la utilidad del Cuestionario SARC-F (cuestionario simple para el diagnóstico de Sarcopenia) y si existe relación entre la masa muscular y la resistencia a la insulina. Métodos: Estudio observacional descriptivo. Se determinó la masa muscular ((bioimpedancia y por absorciometría dual de Rayos X), fuerza (dinamometría manual) y rendimiento muscular (batería SPPB (short physical performance battery) en 88 mujeres entre 45-79 años de edad, con residencia permanente en el Municipio Plaza de la Revolución (Policlínico Vedado). Se estudiaron variables clínicas. Se aplicó el cuestionario SARC-F (A simple Questionnaire to Rapidly Diagnostic for Sarcopenia). Se determinó la relación glucemia/insulinemia en ayunas. Para determinar valores de referencia para disminución de la masa muscular se estudiaron 17 mujeres sanas entre 40-44 años de edad. Análisis estadístico: Uso de tabulaciones cruzadas, Test Kruskall Wallis, y Correlación de Pearson para identificar asociación entre las variables, valor (p<0,05) prueba X2. Resultados: Valor de referencia para baja masa muscular fue <8,33 Kg/m² por DXA y de 15,36 Kg/m² por bioimpedancia. El 18 por ciento del grupo presentó algún grado de sarcopenia que se asoció con resistencia insulina. No fue útil el cuestionario SARF-C. Conclusiones: Se determinó el valor de referencia para masa muscular disminuida, la presencia de sarcopenia y su relación con la resistencia a la insulina(AU)

ABSTRACT Introduction: Decreased muscle mass (sarcopenia) and decreased bone mass (osteopenia or osteoporosis) that occur with aging are associated with the increase of fragility and fractures, which affect quality of life and increase mortality. Reports on muscle mass are scarce in our field. Objectives: Identify the normal reference values of muscle mass in women in the reference area, the frequency of Sarcopenia with the use of the three parameters recommended by the European Consensus, the usefulness of the SARC-F Questionnaire (simple questionnaire for the diagnosis of Sarcopenia) and whether there is a relationship between muscle mass and insulin resistance. Methods: Descriptive observational study. Muscle mass (bioimpedance and dual X-ray absorcimetry), strength (manual dynamometry) and muscle performance (battery SPPB (short physical performance battery) were determined in 88 women between 45-79 years old, with permanent residence in Plaza de la Revolution municipality (Vedado Polyclinic). The clinical variables were studied. The SARC-F questionnaire (A simple Questionnaire to Rapidly Diagnostic for Sarcopenia) was applied. The fasting blood glucose/insulinemic relation was determined. To determine reference values for decreased muscle mass, 17 healthy women between 40-44 years old were studied. Statistical analysis: Use of cross-tabulations, Kruskall Wallis Test, and Pearson Correlation to identify association between variables, value (p<0.05) X2 test. Results: Reference value for low muscle mass was <8.33 Kg/m2 per DXA and 15.36 Kg/m2 per bioimpedance. 18 percent of the group had some degree of sarcopenia that was associated with insulin resistance. The SARF-C questionnaire was not helpful. Conclusions: The reference value for decreased muscle mass, the presence of sarcopenia and its relationship to insulin resistance were determined(AU)

Generalidades de la obesidad sarcopénica en adultos mayores / Generalities of sarcopenic obesity in older adults

Resumen El sobrepeso y la obesidad, definidos como el exceso de grasa corporal, se han convertido en un problema mundial que va en aumento; como resultado del desbalance entre las ingestas y el gasto energético. En los adultos mayores es común la variante de obesidad sarcopénica, la cual es una entidad en la cual no sólo se da un aumento en la masa grasa, sino que también una disminución en la masa muscular. Dentro de las complicaciones que puede traer la obesidad en los adultos mayores están: cáncer, enfermedades cardiovasculares, osteoporosis, diabetes, osteoartritis y el consecuente deterioro en la calidad de vida. Por lo anterior, se hace importante realizar un abordaje integral que involucre intervenciones nutricionales y actividad física a las cuales se pueden sumar, en caso de ser necesario, intervenciones farmacológicas y/o quirúrgicas.

Abstract Overweight and obesity, defined as excess body fat, have become a worldwide problem that is increasing; as result of the imbalance between intakes and energy expenditure. In older adults the variant known as sarcopenic obesity is common, which is an entity where not only there is an increase in fat mass, but also a decrease in lean mass. Among the complications that obesity can bring in older adults are cancer, cardiovascular disease, osteoporosis, diabetes, osteoarthritis and the consequent deterioration in the quality of life. Therefore, it is important to carry out a comprehensive approach that involves nutritional interventions and physical activity to which can be added, if necessary, pharmacological and surgical interventions.

Sarcopenia como factor predictivo de dehiscencia de anastomosis en pacientes operados de cáncer de colon / Predictive value of sarcopenia for anastomotic dehiscense in colon cancer surgery

Resumen Introducción: Una complicación importante de la cirugía colorrectal es la dehiscencia de anastomosis (DA). El estado nutricional es uno de los factores importantes en la DA. Una forma objetiva para evaluar nutricionalmente a los pacientes es medir la sarcopenia, definida como disminución de masa muscular esquelética, que puede ser objetivada por análisis de Unidades Hounsfield (UH) y área muscular (AM) por medio de Tomografía Computarizada de Abdomen y Pelvis (TCAP). Objetivo: Evaluar si existe relación entre la DA y la presencia de sarcopenia detectada por medición de UH y AM en TCAP en pacientes sometidos a colectomía por cáncer. Materiales y Método: Estudio de casos y controles con estadística analítica. Se eligen de manera aleatoria 21 pacientes con DA y 40 sin DA. Se incluyen > 18 años, con colectomía por cáncer y anastomosis primaria. Fueron excluidos pacientes ostomizados, que no tuvieran TCAP preoperatoria o que éste no permitiera medir UH y AM. La evaluación imagenológica fue realizada por radiólogo experto. Resultados: La comparación entre grupos evidencia que son homogéneos con respecto al sexo (predomino hombres), edad (promedio 60 años) y localización. Se evidencia signos imagenológicos sugerentes de sarcopenia en el grupo de DA, puesto que existe disminución en UH con valores estadísticamente significativos y tendencia a presentar valores menores en el AM. Conclusiones: La presencia de sarcopenia evaluada por alteración de UH en estudio radiológico se correlaciona con DA, pudiendo ser un predictor de riesgo. La importancia de este hallazgo es que es un factor de riesgo potencialmente corregible.

Introduction: An important complication of colorectal surgery is anastomotic dehiscence (AD). Nutritional status is one of the important factors in AD. An objective way to evaluate the patients' nutritional status is to measure sarcopenia, which is the reduction of skeletal muscle mass. It is possible to standardize Sarcopenia using the analysis of the Hounsfield Units (HU) and the muscular area (MA) which consider Computed Tomography of Abdomen and Pelvis (CTAP). Aim: To evaluate whether there is a relationship between AD and the presence of sarcopenia detected by the measurement of HU and MA using CTAP. The situation considers patients undergoing colectomy for cancer. Materials and Method: Cases and controls were studied with analytical statistics. 21 patients with AD and 40 without AD were chosen randomly. They include > 18 years, with colectomy for cancer and primary anastomosis. Ostomized patients, who previous the surgery do not have CTAP or if it was not available to measure HU and MA, were excluded. The imaging evaluation was performed by an expert radiologist. Results: The comparison between groups shows that they are homogeneous with respect the sex (predominant men), age (average 60 years) and location. There are signs of imaging which suggest the presence of sarcopenia in the AD group. This is explained because there is an important statistical decrease in the HU values and a tendency to present lower MA values. Conclusions: The presence of sarcopenia due to alteration of HU in a radiological study is correlated with AD, and could be a predictor of risk. The importance of this finding is that this risk factor is potentially correctable.

Rendimiento físico en adultos mayores del Policlínico Héroes del Moncada / Physical performance in elder people of the policlinic Heroes del Moncada

RESUMEN Introducción: la evaluación del rendimiento físico en los adultos mayores es una importante herramienta de trabajo para determinación de la sarcopenia, la fragilidad y evaluar así la capacidad funcional en esta etapa. Objetivo: evaluar el rendimiento físico en adultos mayores del Policlínico "Héroes del Moncada", del municipio Plaza de la Revolución, La Habana. Materiales y método: se realizó una investigación descriptiva, de corte transversal en 422 adultos mayores del Policlínico "Héroes del Moncada" en el período comprendido de mayo 2011 a mayo 2014. Se determinó el rendimiento físico a través de la aplicación del test levantarse cinco veces de una silla y la velocidad de la marcha a 4,5 metros de distancia. Resultados: el 90,3% de los adultos mayores completaron el test Levantarse de una silla 5 veces, con tiempo de 13.8 seg, el valor medio de la velocidad de la marcha fue de 0.74m/seg. Conclusiones: la mayoría de las personas mayores fueron del sexo femenino, de 70 a 79 años, independientes para las actividades básica e instrumentadas de la vida diaria y con buen rendimiento físico (AU).

SUMMARY Introduction: to evaluate physical performance of elder people is an important working tool for determining sarcopenia, frailty and that way assessing the functional capacity at this age. Objective: to evaluate physical performance in elder people from policlinic "Heroes del Moncada". Materials and methods: a cross-sectional, descriptive research was carried out in 422 elder people from the Teaching Policlinic "Heroes del Moncada" in the period from May 2011 to May 2014. Physical performance was determined applying the test staying 5 times up from a chair and measuring the speed of a 4.5- meters-long walk. Results: 90.3 % of the people completed the test staying 5 times up from a chair in 13.8 sec. The average speed of the walk was 0.74 m/sec. Conclusions: most of elder people were female, aged 70-79 years, independent according to the Basic and Instrumented Activities of the Daily Life and showing good physical performance (AU).

Efecto de intervenciones con ejercicio y/o suplementación sobre la masa muscular de personas mayores con sarcopenia: un metaanálisis / Effect of interventions with exercise and/or supplementation on muscle mass of elderly people with sarcopenia: a meta-analysis / Efeito das intervenções com o exercício e / ou a suplementação na massa muscular de idosos com sarcopenia: uma meta-análise

Resumen Solano-García, W. & Carazo-Vargas, P. (2019). Efecto de intervenciones con ejercicio y/o suplementación sobre la masa muscular de personas mayores con sarcopenia: Un metaanálisis. PENSAR EN MOVIMIENTO: Revista de Ciencias del Ejercicio y la Salud, 17(1), 1-22. La sarcopenia se caracteriza por la pérdida de la masa muscular y la fuerza. El objetivo fue determinar el tamaño del efecto global del tratamiento con ejercicio y/o suplementación sobre la masa muscular de personas adultas mayores diagnosticadas con sarcopenia, así como identificar las variables que moderan el efecto del tratamiento. Con respecto al método, se realizó una búsqueda de literatura en las bases de datos EBSCOhost, Ovid, ProQuest, PubMed, ScienceDirect, SpringerLink, Embase. De 4770 estudios recuperados, se incluyeron los 14 que cumplieron los criterios de inclusión: analizar la masa muscular, emplear diseños experimentales, aportar la estadística descriptiva, administrar un programa de ejercicio, suplementación o combinado de estas intervenciones e incluir personas mayores de 60 años diagnosticadas con sarcopenia. Los estudios debían estar publicados en texto completo en inglés o español. El cálculo del tamaño de efecto global se siguió utilizando el modelo de efectos aleatorios. En los resultados, fueron analizados 818 sujetos pertenecientes al grupo experimental y 284 al grupo control. Se obtuvo un tamaño de efecto global de 0.16 (p=0.005), procedente de 38 tamaños de efecto. El gráfico de funnel plot y la prueba de Egger no evidenciaron la presencia de sesgo general, ni publicación. Se necesitan 23 estudios para que el tamaño de efecto global sea no significativo. En la conclusión, se evidencia un cambio significativo en la masa muscular de personas adultas mayores diagnosticadas con sarcopenia, utilizando el tipo de intervención de ejercicio contra-resistencia con o sin suplementación; asimismo, se establece una guía de recomendaciones sobre prescripción de ejercicio y suplementación.

Abstract Solano-García, W. & Carazo-Vargas, P. (2019). Effect of interventions with exercise and/or supplementation on muscle mass of elderly people with sarcopenia: a meta-analysis. PENSAR EN MOVIMIENTO: Revista de Ciencias del Ejercicio y la Salud, 17(1), 1-22. Sarcopenia is characterized by the loss of muscle mass and strength. The objective of this paper was to determine the size of the overall effect of a treatment based on exercise and/or supplementation on muscle mass in elderly adults diagnosed with Sarcopenia, as well as identify the variables that can moderate the effect of the treatment. Regarding the method used, the EBSCOhost, Ovid, ProQuest, PubMed, ScienceDirect, SpringerLink, and Embase databases were consulted. Out of the 4770 studies recovered, 14 met the following criteria: analysis of muscle mass; use of experimental designs; use of descriptive statistics; administration of a program based on exercise, supplementation, or both; and subjects being over 60 diagnosed with sarcopenia. The studies were also required to be published completely in English or Spanish. The size of the global effect was calculated following the random effects model. A total of 818 and 284 subjects were analyzed in the experimental group and in the control group, respectively. An overall effect size of 0.16 (p = 0.005) was obtained from 38 effect sizes. The Funnel Plot graph and the Egger test did not reveal any evidence of presence of general bias or publication. A total of 23 studies are needed for the global effect size not to be significant. In conclusion, a significant change in the muscle mass of elderly adults diagnosed with sarcopenia was evident when having a resistance exercise intervention, with or without supplementation. A guide of recommendations on supplementation and exercise prescription was also established in the paper.

Resumo Solano-García, W. & Carazo-Vargas, P. (2019). Efeito das intervenções com o exercício e / ou a suplementação na massa muscular de idosos com sarcopenia: Uma meta-análise. PENSAR EN MOVIMIENTO: Revista de Ciencias del Ejercicio y la Salud, 17(1), 1-22. A sarcopenia é caracterizada pela perda de massa e força muscular. O objetivo foi determinar o tamanho do efeito global sobre a massa muscular no tratamento com exercício e/ou suplementação em idosos diagnosticados com sarcopenia e identificar as variáveis que moderam o efeito do tratamento. Com relação ao método, foi realizada uma pesquisa bibliográfica nas bases de dados EBSCOhost, Ovid, ProQuest, PubMed, ScienceDirect, SpringerLink, Embase. Dentre os 4770 estudos recuperados foram incluídos 14 que preencheram os critérios de inclusão, ou seja, analisar a massa muscular, usar desenhos experimentais, fornecer estatísticas descritivas, administrar um programa de exercício, suplementação ou a combinação dessas intervenções e incluir pessoas com mais de 60 anos de idade diagnosticadas com sarcopenia. Os estudos deveriam ter sido publicados em texto completo em inglês ou espanhol. Para o cálculo do tamanho do efeito global continuou-se usando o modelo de efeitos aleatórios. Nos resultados, 818 indivíduos pertencentes ao grupo experimental e 284 ao grupo controle foram analisados. Obteve-se um tamanho de efeito global de 0,16 (p = 0,005), a partir de 38 tamanhos de efeito. O gráfico de funnel plot e o teste de Egger não mostraram a presença de viés geral ou publicação. São necessários 23 estudos para que o tamanho do efeito global não seja significativo. Na conclusão, há uma mudança significativa na massa muscular de idosos diagnosticados com sarcopenia, utilizando o tipo de intervenção do exercício contrarresistência com ou sem suplementação; igualmente, fica estabelecido um guia de recomendações sobre prescrição de exercícios e suplementação.

Resumen ejecutivo guía de práctica clínica sarcopenia / executive summary clinical practice guideline sarcopenia

Favorecer el adecuado manejo clínico integral de las personas de 65 añosy más con diagnóstico de Sarcopenia, tanto primaria como secundaria Todas las personas con Sarcopenia primaria y secundaria que reciban atención en los niveles primarios, secundarios y terciarios de salud en los sectores públicos y privados del territorio nacional. Cualesquiera de los profesionales de salud con responsabilidades en personas con Sarcopenia: médicos geriatras, generales y de especialidades afines, equipos de salud de atención primaria, secundaria y terciaria, centros de atención de personas mayores, enfermeras, kinesiólogos, nutricionistas, terapeutas ocupacionales, químicos farmacéuticos, trabajadores sociales y otros. Las recomendaciones de esta Guía fueron elaboradas de acuerdo con el sistema "Grading of Recommendations Assessment, Development, and Evaluation" (GRADE). Luego de priorizadas las preguntas a responder, se realizó la búsqueda y la síntesis de evidencia, para finalmente generar las recomendaciones a través del juicio del Panel de Expertos